FDA could approve Pfizer COVID-19 booster by week’s end: report

Fda Could Approve Pfizer Covid-19 Booster By Week’S End: Report

Federal agencies could authorize COVID-19 booster shots for all adults by the end of the week, a rapid turnaround that comes just over a week after Pfizer and BioNTech filed their request with the Food and Drug Administration.

FDA regulators want to take action by Thursday, according to The New York Times, and the Centers for Disease Control and Prevention scheduled a three-hour meeting of their Advisory Committee on Immunization Practices (ACIP) Friday to discuss boosters.

The approval from both agencies would open the floodgates for the third dose for all adults. At this point, subgroups who received the Pfizer or Moderna injections at least six months ago can come forward for an additional dose, and individuals who received the Johnson & Johnson vaccine at least two months ago can request a booster .

However, states began to get ahead of the FBI. New York City on Monday told health care providers not to turn people away if they were looking for a booster, and Arkansas, California, Colorado and New Mexico opened their doors to all adults.

The Biden administration is pushing for additional doses amid signs of vaccine potency waning after six months, and as cases increase on the eve of the holiday season.

The FDA is not expected to consult with an outside advisory group that put the brakes on President Biden’s pursuit of widespread boosters about two months ago.

Members of the group have generally supported boosters for the elderly and the medically frail, but have taken a tougher line on boosters for the young. They say the shots appear to be holding up to avoid hospitalization and death, and they need to analyze the risk of myocarditis, or inflammation of the heart muscle, which sometimes occurs after vaccination, especially in teenage or young adult males.

“I am disappointed that our committee was not given the opportunity to review this recommendation,” said Dr. Paul Offit, professor of pediatrics at the University of Pennsylvania and member of the advisory panel, told The Washington Times. “I think it would have been valuable for the public to hear our deliberations on this. Looking forward to the ACIP discussion on Friday.”

Google News Follow 1
FDA could approve Pfizer COVID-19 booster by week's end: report 3

Leave a Reply